Smartkarma Research Team, Smartkarma

Smartkarma Research

Smartkarma Research Team

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<p>For our next Corporate Webinar, we are glad to welcome RemeGen's Chief Financial Officer, Mr. Tong Shaojing.</p>
<p>In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, <a href="https://www.smartkarma.com/profiles/eric-wen" target="_blank" data-smartkarma-citation="accounts:54017" rel="noopener">Eric Wen</a> . The Corporate Webinar will include a live Q&amp;A session.</p>
<h3>The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.</h3>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div class="content-highlight">
<h2><a href="https://share.hsforms.com/1H9pFZOB-RF2J00kbvMmxcw2c5gj?zoom_webinar_id=88131022121" target="_blank" rel="noopener">Register for the Webinar here</a></h2>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<h3>About RemeGen</h3>
<p>RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.</p>

For our next Corporate Webinar, we are glad to welcome RemeGen's Chief Financial Officer, Mr. Tong Shaojing.
In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Eric Wen . The Corporate Webinar will include a live Q&amp;A session.
The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.












Register for the Webinar here












About RemeGen
RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

Shin Kong Financial Holding / Event-Driven

<ul>
<li>In late August, <a href="https://www.smartkarma.com/entities/taishin-financial-holding" target="_blank" data-smartkarma-citation="entities:715:1" rel="noopener">Taishin Financial Holding (2887 TT)</a> and <a href="https://www.smartkarma.com/entities/shin-kong-financial-holding" target="_blank" data-smartkarma-citation="entities:15351:1" rel="noopener">Shin Kong Financial Holding (2888 TT)</a> agreed to merge in what appeared to be a hastily papered deal discussed <a href="https://www.smartkarma.com/insights/shin-kong-2888-tw-and-taishin-2887-tw-agree-to-merge-but-it-isn-t-clean-and-it-s-a-bad-price" target="_blank" rel="noopener">here</a>.</li>
<li>
<a href="https://www.smartkarma.com/entities/ctbc-financial-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:436:1" rel="noopener">CTBC Financial Holding (2891 TT)</a> put forth its own proposal at a big premium. Shin Kong traded up. Both deals need FSC approval. Taishin's deal has a vote 9 October. </li>
<li>Taishin recently upped terms. And now the FSC has said "no" to CTBC's proposal. But it's weird. It's not "NO"; more like, "not this." Bit of a sticky wicket here.</li>
</ul>


In late August, Taishin Financial Holding (2887 TT) and Shin Kong Financial Holding (2888 TT) agreed to merge in what appeared to be a hastily papered deal discussed here.

CTBC Financial Holding (2891 TT) put forth its own proposal at a big premium. Shin Kong traded up. Both deals need FSC approval. Taishin's deal has a vote 9 October. 
Taishin recently upped terms. And now the FSC has said "no" to CTBC's proposal. But it's weird. It's not "NO"; more like, "not this." Bit of a sticky wicket here.


Competition to Take Over Shin Kong (2888 TT) - CTBC in a Bit of a A Sticky Wicket, Wot?

Japan Specialist

Mark Chadwick

Thematic (Sector/Industry)

<ul>
<li>U.S. stocks closed with modest losses on Wednesday after the Federal Reserve cut interest rates by 50 basis points</li>
<li>The Fed’s projections suggest a fed funds rate of 4.4% by 2024, with further easing into 2025</li>
<li>Japan's exports grew 5.6% in August, marking the ninth consecutive month of increase. Semiconductor-related goods drove growth</li>
</ul>


U.S. stocks closed with modest losses on Wednesday after the Federal Reserve cut interest rates by 50 basis points
The Fed’s projections suggest a fed funds rate of 4.4% by 2024, with further easing into 2025
Japan's exports grew 5.6% in August, marking the ninth consecutive month of increase. Semiconductor-related goods drove growth


Ohayo Japan | Fed Signals Two More Rate Cuts in 2024

Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

Korea / Special Sits, Pairs, Index Rebalancing

Clepsydra Capital

Investigate special situations, pairs, and index rebalancing trades in Korea.

<ul>
<li>As of today, it’s clear Choi is struggling to secure white knights, pushing him to double down on political lobbying to stay in the game.</li>
<li>Choi's aiming for the National Pension Service’s 7.57% voting rights, but with its legal neutrality, the chances of it caving to political pressure are slim.</li>
<li>MBK’s statement today shows confidence that Choi won’t get Fair Trade Commission approval, and that, like Hanwha and LG, Hyundai Motor won’t back him either.</li>
</ul>


As of today, it’s clear Choi is struggling to secure white knights, pushing him to double down on political lobbying to stay in the game.
Choi's aiming for the National Pension Service’s 7.57% voting rights, but with its legal neutrality, the chances of it caving to political pressure are slim.
MBK’s statement today shows confidence that Choi won’t get Fair Trade Commission approval, and that, like Hanwha and LG, Hyundai Motor won’t back him either.


Trading Insights from Today’s Dramatic Developments in the Korea Zinc Event

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

<ul>
<li>Following its acquisition by Nationwide, <a href="https://www.smartkarma.com/entities/virgin-money-uk-plc" target="_blank" data-smartkarma-citation="entities:22918:1" rel="noopener">Virgin Money UK Plc (VUK AU)</a> is scheduled to stop trading on the <a href="https://www.smartkarma.com/entities/asx-ltd" target="_blank" data-smartkarma-citation="entities:552:1" rel="noopener">ASX Ltd (ASX AU)</a> after market close on 25 September.</li>
<li>
<a href="https://www.smartkarma.com/entities/virgin-money-uk-plc" target="_blank" data-smartkarma-citation="entities:22918:1" rel="noopener">Virgin Money UK Plc (VUK AU)</a> is a member of the S&amp;P/ASX100 Index and <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a> and there will be adhoc inclusions at the close on 25 September.</li>
<li>There are a couple of stocks vying for inclusion in each index and the next couple of days will determine which ones make it.</li>
</ul>


Following its acquisition by Nationwide, Virgin Money UK Plc (VUK AU) is scheduled to stop trading on the ASX Ltd (ASX AU) after market close on 25 September.

Virgin Money UK Plc (VUK AU) is a member of the S&amp;P/ASX100 Index and S&amp;P/ASX 200 (AS51 INDEX) and there will be adhoc inclusions at the close on 25 September.
There are a couple of stocks vying for inclusion in each index and the next couple of days will determine which ones make it.


ASX100/ASX200 Index: Replacement Candidates for Virgin Money (VUK AU)

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

RemeGen (9995 HK) is a leading biotech company committed to the discovery, development, and commercialization of innovative biologic drugs. Learn...

Smartkarma Research

Competition to Take Over Shin Kong (2888 TT) - CTBC in a Bit of a A Sticky Wicket, Wot?

Taishin has upped the terms for Shin Kong to be closer to the CTBC terms, and now the FSC has rejected the CTBC bid. But CTBC will re-submit,...

Travis Lundy

Ohayo Japan | Fed Signals Two More Rate Cuts in 2024

U.S. stocks dip after Fed cuts rates, while Japan's exports rise for ninth straight month led by semiconductor sales. Fed projects further easing...

Mark Chadwick

Trading Insights from Today’s Dramatic Developments in the Korea Zinc Event

This post offers trading insights into today’s dramatic developments involving both parties in the Korea Zinc tender offer event.

Sanghyun Park

ASX100/ASX200 Index: Replacement Candidates for Virgin Money (VUK AU)

Virgin Money will stop trading after the close on 25 Sep. There will be ad hoc adds to the ASX100 and ASX200. There are 2 stocks vying for...

Brian Freitas

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

RemeGen (9995 HK) is a leading biotech company committed to the discovery, development, and commercialization of innovative biologic drugs. Learn...

Smartkarma Research

Competition to Take Over Shin Kong (2888 TT) - CTBC in a Bit of a A Sticky Wicket, Wot?

Taishin has upped the terms for Shin Kong to be closer to the CTBC terms, and now the FSC has rejected the CTBC bid. But CTBC will re-submit,...

Travis Lundy

Ohayo Japan | Fed Signals Two More Rate Cuts in 2024

​U.S. stocks dip after Fed cuts rates, while Japan's exports rise for ninth straight month led by semiconductor sales. Fed projects further easing...

Mark Chadwick

Trading Insights from Today’s Dramatic Developments in the Korea Zinc Event

This post offers trading insights into today’s dramatic developments involving both parties in the Korea Zinc tender offer event.

Sanghyun Park

ASX100/ASX200 Index: Replacement Candidates for Virgin Money (VUK AU)

Virgin Money will stop trading after the close on 25 Sep. There will be ad hoc adds to the ASX100 and ASX200. There are 2 stocks vying for...

Brian Freitas

U.S. stocks dip after Fed cuts rates, while Japan's exports rise for ninth straight month led by semiconductor sales. Fed projects further easing...